IDA Ireland has published a new white paper entitled “The Future of Biopharma in Ireland: Unlocking Growth Potential Through Innovation, Investment, and Collaboration.” The report provides current assessments of the country's development as a globally significant location for biopharmaceutical production. It outlines strategic ways in which Ireland can further consolidate its role in international competition. The white paper is based on contributions from leading figures in the Irish biopharmaceutical sector, who exchanged views on key future issues during a roundtable discussion.
Biopharmaceutical production in Ireland
The white paper makes it clear that Ireland's importance in the industry's global production network continues to grow. It highlights the country's stable geopolitical situation, high regulatory standards, and excellently trained workforce. Against the backdrop of increasing uncertainties in global trade, Ireland is considered a reliable production and supply chain partner for the international pharmaceutical industry.
Future fields: novel therapies and next-generation biologics
One focus of the report is Ireland's growing role in the manufacture of modern forms of therapy. This includes the production of cell-, gene- and RNA-based drugs, as well as the development and manufacture of the next generation of biologics. Particular emphasis is placed on the importance of investment in modern infrastructure, such as the National Institute for Bioprocessing Research and Training, which serves as a core component of the Irish innovation ecosystem.
Digital transformation and AI as drivers for biopharmaceutical production
Ireland is increasingly becoming a hub for digital and AI-supported production processes. Close cooperation between industry, research, and government agencies is creating the conditions for Biopharma 4.0, leading to greater efficiency, improved compliance, and faster technological innovation cycles. The white paper describes how data analytics and automated processes are increasingly becoming standard practice along the value chain.
Ireland's contribution to regulatory and industrial policy strategies
The report also shows how Ireland is actively involved in the further development of European life sciences strategies. A cross-agency approach strengthens international competitiveness, promotes the development of new talent, and supports sustainable growth. Ireland's role as a driving force within the EU is clearly outlined.
Over more than six decades, Ireland has developed into a leading biopharmaceutical cluster. Today, the industry employs more than 50,000 people and has attracted around €15 billion in foreign direct investment over the past ten years. A strong combination of innovation, regulatory quality, and close cooperation between industry and government ensures that Ireland will remain internationally competitive in biopharmaceutical production in the future.
Ireland as a trusted and resilient location for biopharmaceutical production
Rory Mullen, Head of Biopharma and Food at IDA Ireland, emphasizes, that Ireland's role as a trusted and resilient manufacturing location for advanced therapy medicinal products offers significant advantages in times of geopolitical uncertainty. The investments of the country in skilled labor, infrastructure, and innovation enable us to meet the future demands of the biopharmaceutical industry, particularly with regard to advanced therapies and digital transformation. You can download the white paper here.
